Get the Stockscreener App
2.10
7.49%
-0.17
Biocardia Inc stock is traded at $2.10, with a volume of 48,661.
It is down -7.49% in the last 24 hours and down -17.97% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$2.27
Open:
$2.24
24h Volume:
48,661
Relative Volume:
0.74
Market Cap:
$9.63M
Revenue:
$468.00K
Net Income/Loss:
$-10.34M
P/E Ratio:
-0.2979
EPS:
-7.05
Net Cash Flow:
$-8.94M
1W Performance:
-21.64%
1M Performance:
-17.97%
6M Performance:
-25.27%
1Y Performance:
-64.38%
1-Day Range:
$2.04
$2.24
1-Week Range:
$2.04
$2.95
52-Week Range:
$1.625
$6.15
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.64 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1672 | 352.85M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.34 | 278.60M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.05 | 144.42M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.20 | 137.80M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
Trial Results Show Autologous Cell Therapy Improves Survival, QOL and Reduces Cardiac Events in Distressed Heart Failure Patients - Diagnostic and Interventional Cardiology
Financial Analysis: BioCardia Inc (BCDA)’s Ratios Unveil Key Insights - DWinneX
BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Call Transcript - Insider Monkey
BioCardia Clarifies Timing for CardiAMP-HF Results Call - MSN
BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... - Yahoo Finance
ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains - Yahoo
BioCardia reports promising two-year CardiAMP trial results By Investing.com - Investing.com South Africa
Earnings call transcript: BioCardia Q4 2024 sees reduced expenses, stock down - Investing.com India
BioCardia Phase 3 CARDIAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years - HMP Global Learning Network
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today - Barchart.com
Critical CardiAMP-HF 2-Year Data Reveal: Key Findings Presentation Today - Stock Titan
BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint - MarketScreener
BioCardia reports promising two-year CardiAMP trial results - Investing.com
BioCardia Reports Positive Phase 3 CardiAMP-HF Results - TipRanks
Breakthrough Heart Failure Treatment Shows 47% Death Risk Reduction in Phase 3 Trial - Stock Titan
BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Beating Heart Patch Market Projected To Witness Substantial - openPR.com
BioCardia Reports 2024 Business Highlights and Financial Results - The Manila Times
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BCDABiocardia Inc Latest Stock News & Market Updates - StockTitan
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings - GuruFocus
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - The Manila Times
BioCardia, Inc. to Report 2024 Financial Results and Host Conference Call Following CardiAMP-HF Trial Presentation - Nasdaq
SBA Communications (SBAC) Gets a Buy from Barclays - The Globe and Mail
MindMed Appoints Matt Wiley as Chief Commercial Officer - The Globe and Mail
Reviewing BioCardia (NASDAQ:BCDA) & Moderna (NASDAQ:MRNA) - Defense World
UiPath (PATH) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
BioCardia secures new Japanese patent for heart therapy delivery By Investing.com - Investing.com Australia
BioCardia Gets Patent in Japan for Helix Biotherapeutic Delivery System -March 10, 2025 at 02:53 pm EDT - Marketscreener.com
BioCardia secures new Japanese patent for heart therapy delivery - Investing.com
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System - The Manila Times
BioCardia announces Japanese patent for Helix system - TipRanks
BioCardia Wins Patent Protection in Japan for Novel Heart Therapy System - StockTitan
BioCardia director Simon Stertzer acquires $2,450 in stock By Investing.com - Investing.com Australia
BioCardia director Simon Stertzer acquires $2,450 in stock - Investing.com
Director’s Bold Move: Major Stock Purchase Signals Confidence in BioCardia - TipRanks
Biocardia director Simon Stertzer acquires $88,064 in stock By Investing.com - Investing.com South Africa
Biocardia director Simon Stertzer acquires $88,064 in stock - Investing.com India
Biocardia CEO Peter Altman buys $1,055 in company stock - Investing.com
BioCardia Announces Primary Data Freeze For CardiAMP HF Phase 3 Trial For ACC 2025 Presentation - Nasdaq
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions - The Manila Times
BioCardia wraps up Phase 3 CardiAMP HF study data - Investing.com India
BioCardia finishes data freezing in heart failure therapy study for presentation - TipRanks
BioCardia Completes Source Data Verification for Phase 3 CardiAMP HF Study on Heart Failure Treatment - Nasdaq
BioCardia Announces Primary Outcome Measures Data Freeze in - GlobeNewswire
Will BioCardia's Cell Therapy Revolutionize Heart Failure Treatment? Phase 3 Data Coming Soon - StockTitan
BioCardia completes enrollment for heart therapy trial By Investing.com - Investing.com Canada
BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) - The Manila Times
BioCardia completes enrollment for heart therapy trial - Investing.com
BioCardia Reports Completion Of Low Dose Cohort Enrollment For Cardiallo Phase I/II Clinical Trial - Marketscreener.com
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):